DaVita Inc. (NYSE:DVA) Shares Purchased by Cetera Investment Advisers

Cetera Investment Advisers increased its position in shares of DaVita Inc. (NYSE:DVA) by 56.9% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 7,658 shares of the company’s stock after purchasing an additional 2,778 shares during the period. Cetera Investment Advisers’ holdings in DaVita were worth $1,171,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Northern Trust Corp boosted its stake in DaVita by 12.5% during the fourth quarter. Northern Trust Corp now owns 740,774 shares of the company’s stock worth $110,783,000 after buying an additional 82,326 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in DaVita by 14.0% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 466,046 shares of the company’s stock worth $69,697,000 after buying an additional 57,386 shares during the period. Deutsche Bank AG boosted its stake in DaVita by 35.2% during the fourth quarter. Deutsche Bank AG now owns 392,422 shares of the company’s stock worth $58,687,000 after buying an additional 102,230 shares during the period. Epoch Investment Partners Inc. purchased a new position in DaVita during the fourth quarter worth about $55,100,000. Finally, Iron Triangle Partners LP purchased a new position in DaVita during the fourth quarter worth about $38,946,000. 90.12% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

DVA has been the subject of several research analyst reports. Truist Financial set a $148.00 target price on shares of DaVita in a research note on Friday. Barclays lowered their target price on shares of DaVita from $169.00 to $160.00 and set an “equal weight” rating for the company in a research note on Thursday, August 7th. Finally, Wall Street Zen raised shares of DaVita from a “hold” rating to a “buy” rating in a research note on Friday, April 25th.

Insider Activity at DaVita

In related news, insider James O. Hearty sold 2,351 shares of the firm’s stock in a transaction that occurred on Wednesday, July 23rd. The shares were sold at an average price of $150.00, for a total value of $352,650.00. Following the sale, the insider owned 26,038 shares of the company’s stock, valued at $3,905,700. This trade represents a 8.28% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 1.50% of the company’s stock.

DaVita Trading Down 0.2%

NYSE DVA opened at $129.22 on Tuesday. The firm has a 50 day simple moving average of $139.92 and a 200-day simple moving average of $146.19. The company has a debt-to-equity ratio of 23.18, a quick ratio of 1.34 and a current ratio of 1.39. DaVita Inc. has a one year low of $126.07 and a one year high of $179.60. The firm has a market cap of $9.24 billion, a price-to-earnings ratio of 12.71, a PEG ratio of 0.93 and a beta of 1.09.

DaVita (NYSE:DVA) last posted its quarterly earnings data on Tuesday, August 5th. The company reported $2.95 EPS for the quarter, beating the consensus estimate of $2.70 by $0.25. DaVita had a net margin of 6.35% and a return on equity of 369.39%. The business had revenue of $3.38 billion during the quarter, compared to analyst estimates of $3.36 billion. During the same quarter last year, the firm posted $2.00 earnings per share. The business’s revenue for the quarter was up 6.1% compared to the same quarter last year. Equities research analysts anticipate that DaVita Inc. will post 10.76 EPS for the current fiscal year.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.